Why aren’t private-label ustekinumab biosimilars getting Medicare Part D coverage?

Because Medicare Part D’s redesigned economics under the Inflation Reduction Act change formulary incentives. Drug Channels argued that unlike in commercial plans, PBM-affiliated manufacturers must weigh statutory Part D discount liability and plan claim exposure, making affiliated private-label biosimilars like Cordavis Pyzchiva and Nuvaila Wezlana less attractive.